The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

N-Acetyl Selank Amidate

NASA · N-Acetyl Selank Amidate · Selank Amidate

C
Animal replicated
Research chemicalSelank AnalogTuftsin-Derived PeptideAnxiolytic Peptide
RouteNasalGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
NASA / N-Acetyl Selank / Selank Amidate — Stabilized Analog of Selank (TP-7) — Selank Analog, Tuftsin-Derived Peptide, Anxiolytic Peptide.
Why people use it
Used primarily for cognitive support and sleep and recovery.
If you only read one thing

NASA has compelling evidence for its mechanism and a plausible pharmacokinetic improvement over Selank — but all controlled trial evidence is for Selank, not NASA. The reasonable inference that NASA produces the same effects as Selank (because it has the same core sequence and the modifications are stability-focused rather than pharmacodynamic) is chemically sound but clinically unproven. This chapter provides the Selank evidence base as the reference, treats NASA as the pharmacokinetically optimized delivery form, and is honest about where the evidence gap lies. Anyone making clinical or personal-use decisions based on this chapter should understand they are applying Selank evidence to a NASA context — the best available approach, but not the same as direct NASA controlled evidence.

Check interactions →
Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit
Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat
Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor
Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot
See route notes
Evidence varies by use case
Evidence reality check
Risk posture
No major flags listed
Review route-specific cautions before use.
Categories
Cognition & MoodSleep & RecoveryImmune & Thymic
Properties
Not injectable
Evidence
CAnimal replicated
The Lineage
Tuftsin (Thr-Lys-Pro-Arg): endogenous tetrapeptide derived from IgG gamma-globulin; immunomodulatory; activates macrophages and NK cells. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, TP-7): synthetic heptapeptide developed at the Institute of Molecular Genetics, Russian Academy of Sciences; tuftsin core + Pro-Gly-Pro C-terminal extension added for metabolic stability and CNS penetration; Russian Ministry of Health approved for GAD and neurasthenia (2009); marketed as Selanc® nasal drops. N-Acetyl Selank Amidate (NASA): Selank with N-terminal acetylation + C-terminal amidation; these chemical modifications protect both termini from aminopeptidase and carboxypeptidase degradation; extends effective half-life; improves stability in nasal spray formulations.
The Key Evidence Gap
Almost all controlled clinical evidence is for Selank, not NASA. NASA's efficacy is inferred from: (1) identical core amino acid sequence; (2) N-acetyl/amidate modifications designed to preserve activity while improving stability. No randomized controlled trial has tested NASA specifically against placebo or active comparator. This is the most important fact for any practitioner or community user to understand. The chapter treats Selank evidence as the reference standard and NASA as a pharmacokinetically improved delivery format.
Selank Russian Approval
Approved by Russian Ministry of Health (2009) for generalized anxiety disorder (GAD) and neurasthenic conditions. Marketed as Selanc® intranasal drops at 0.15% concentration. This is a genuine national regulatory approval — not just research use. It is not FDA or EMA approval. The compound went through the Russian clinical trial and regulatory process; the methodology and oversight differ from FDA standards but the approval is not trivial.
The Anxiolytic Profile — What Makes It Different
Selank's anxiolytic profile is characterized by properties that distinguish it from benzodiazepines: reduces anxiety (comparable to benzodiazepines in Russian trials); DOES NOT produce sedation; DOES NOT produce cognitive impairment; DOES NOT produce tolerance or dependence; produces ADDITIONAL psychostimulant and cognitive enhancement effects that benzodiazepines lack. This profile — anxiolytic + pro-cognitive — is the defining clinical value proposition of the Selank family. No Western pharmaceutical anxiolytic combines these properties in this way.
Mechanisms (Multiple)
GABA-A allosteric modulation: Selank influences GABA-A receptor subunit gene expression (Inozemtsev 2008); increases GABA-A receptor density; does NOT directly bind benzodiazepine receptor site (not a classical BZD). Enkephalin stabilization: inhibits enkephalin-degrading enzymes (enkephalinase inhibition); raises endogenous leu-enkephalin and met-enkephalin levels; indirect opioid-like anxiolytic and mood effects without opioid receptor binding. BDNF upregulation: increases hippocampal BDNF; promotes neuroplasticity; potential antidepressant mechanism. Serotonin modulation: region-specific changes in 5-HT metabolism. Dopamine/norepinephrine: monoamine system modulation documented in animal studies.
Formulations
Selank: 0.15% intranasal drops (Selanc®, Russia); SubQ injection (research). N-Acetyl Selank Amidate (NASA): not commercially approved anywhere; available as research chemical; nasal spray (common format; 200-400 mcg/pump) or SubQ injection (100-200 mcg). The N-acetyl/amidate modifications are specifically valuable for nasal spray formulation stability — protecting the peptide during shelf life and administration from enzymatic degradation at the nasal mucosa.
WADA / Regulatory
Not on the WADA Prohibited List. Not FDA-approved. Not EMA-approved. Selank is Russian Ministry of Health approved for specific indications. NASA has no regulatory approval anywhere. Both are research chemicals in the US/EU context. No HPTA effects; no anabolic effects; no anti-doping concern.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Naltrexone / LDN
C
Shared goal · cognition

FDA-Approved at 50 mg for Opioid and Alcohol Use Disorder Since 1984. Off-Label at 1.5-4.5 mg (LDN) — Two Completely Different Mechanisms at Two Completely Different Doses. TLR4 Blockade on Microglia. The Endorphin Rebound. A Lancet Rheumatology RCT in 2024. An Evidence Base Growing Faster Than Pharma Has Any Reason to Fund. The Most Favorably Tolerated Prescription Drug in Its Evidence Literature.

Selank
C
Shared goal · cognition

Russia Approved It. The West Has Never Independently Validated It. And It Might Be the Only Anxiolytic That Doesn't Make You Stupid.

DSIP
C
Shared goal · cognition

Isolated 1977. Named for Sleep. 40+ Years of Research. No Gene Found. No Specific Receptor Identified. Half-Life 15 Minutes In Vitro — Yet Produces Multi-Night Effects. Studied for Sleep, Stress, Alcohol Withdrawal, Opiate Withdrawal, Neuroprotection, and Longevity. The Most Mechanistically Mysterious Compound in this reference.

Check interactions